argenx SE: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
argenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
How this was made
The 30-second read
Why it matters
The tender offer commencement is a primary M&A catalyst. Traders can model deal spread behavior using the fixed $77 cash consideration, the Aug. 26 expiration, and the HSR-related condition.
Market read
A fresh tender offer at a specified cash price with defined expiration and conditions typically drives immediate repricing and event-trade opportunities in both the acquirer and target.
What to watch
No financing condition is stated, but the minimum condition (tendered shares representing one more than 50% post-consummation) can still create execution risk and spread volatility if tendering lags.
Background
argenx and Forte entered a Merger Agreement dated July 26, 2026; this release announces the start of the tender offer and outlines merger mechanics and conditions.
Ticker impact
argenx commenced a tender offer via its subsidiary to acquire Forte, offering $77.00 per share in cash and setting deal conditions.
Likely positive bias for ARGX on deal momentum, with volatility around tender acceptance and regulatory/HSR timing.
The article discloses a fresh tender offer commencement, a concrete bid price, and key conditions (including HSR waiting period), which typically drives immediate repricing and event-driven trading.
Forte is the target of argenx’s tender offer to purchase all outstanding shares for $77.00 per share, with expiration on Aug. 26, 2026.
Likely supportive for FBRX toward the $77 offer price, with potential premium/discount swings as deal conditions and extension risk evolve.
The text provides the bid price, tender mechanics, and that Forte’s board recommends acceptance via a filed Schedule 14D-9, which are primary inputs for spread and arbitrage positioning.
Market effects
Reinforces ongoing consolidation in immunology/biopharma and may lift sentiment for similar small-to-mid cap targets.
Limited direct macro impact; primarily US biotech and European biotech M&A sentiment.
Moderate, as it is a single-company deal but can influence broader deal-risk appetite in biotech.
Counterpoint
Even with a stated $77 price, deal completion risk remains due to HSR waiting period expiration/termination and the minimum tender condition threshold.
Key entities
- acquirerargenx
Immunology company commencing the tender offer via a wholly-owned subsidiary.
- targetForte Biosciences, Inc.
Clinical-stage biopharma company receiving the $77.00 per share cash tender offer.
- deal vehicleAvena Merger Sub Inc.
Wholly-owned subsidiary of argenx making the tender offer to purchase Forte shares.
- governanceForte Board of Directors
Published Schedule 14D-9 recommending Forte stockholders accept the offer.
